DE69322275T2 - Azazyklische verbindungen - Google Patents
Azazyklische verbindungenInfo
- Publication number
- DE69322275T2 DE69322275T2 DE69322275T DE69322275T DE69322275T2 DE 69322275 T2 DE69322275 T2 DE 69322275T2 DE 69322275 T DE69322275 T DE 69322275T DE 69322275 T DE69322275 T DE 69322275T DE 69322275 T2 DE69322275 T2 DE 69322275T2
- Authority
- DE
- Germany
- Prior art keywords
- pct
- 6alkyl
- conrarb
- conr13c2
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 229910003827 NRaRb Inorganic materials 0.000 abstract 1
- 102000003141 Tachykinin Human genes 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 108060008037 tachykinin Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929216065A GB9216065D0 (en) | 1992-07-28 | 1992-07-28 | Therapeutic agents |
| GB929216304A GB9216304D0 (en) | 1992-07-31 | 1992-07-31 | Therapeutic agents |
| GB929224918A GB9224918D0 (en) | 1992-11-27 | 1992-11-27 | Therapeutic agents |
| GB929226058A GB9226058D0 (en) | 1992-12-14 | 1992-12-14 | Therapeutic agents |
| PCT/GB1993/001525 WO1994002461A1 (en) | 1992-07-28 | 1993-07-20 | Azacyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69322275D1 DE69322275D1 (de) | 1999-01-07 |
| DE69322275T2 true DE69322275T2 (de) | 1999-06-24 |
Family
ID=27450911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69322275T Expired - Fee Related DE69322275T2 (de) | 1992-07-28 | 1993-07-20 | Azazyklische verbindungen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5561130A (de) |
| EP (1) | EP0652866B1 (de) |
| JP (1) | JPH07508993A (de) |
| AT (1) | ATE173725T1 (de) |
| AU (1) | AU675447B2 (de) |
| CA (1) | CA2138650A1 (de) |
| DE (1) | DE69322275T2 (de) |
| ES (1) | ES2124318T3 (de) |
| WO (1) | WO1994002461A1 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9402688D0 (en) * | 1994-02-11 | 1994-04-06 | Merck Sharp & Dohme | Therapeutic agents |
| US5750549A (en) * | 1996-10-15 | 1998-05-12 | Merck & Co., Inc. | Cycloalkyl tachykinin receptor antagonists |
| EP1296888B1 (de) | 2000-07-03 | 2006-02-15 | Zakrytoe Aktsionernoe Obschestvo OSTIM | Verfahren zur herstellung von nanodimentioniertem kristallinem hydroxyapatit |
| MX2007000428A (es) | 2004-07-15 | 2008-03-05 | Amr Technology Inc | Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina. |
| ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
| CA2615403C (en) | 2005-07-15 | 2015-06-16 | Amr Technology, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| GB0606985D0 (en) * | 2006-04-07 | 2006-05-17 | Merck Sharp & Dohme | Therapeutic agents |
| CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| EP2109608B1 (de) | 2007-01-10 | 2011-03-23 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Amidsubstituierte indazole als poly-(adp-ribose)-polymerase (parp)-hemmer |
| US8106086B2 (en) | 2007-04-02 | 2012-01-31 | Msd K.K. | Indoledione derivative |
| JP5501227B2 (ja) | 2007-06-27 | 2014-05-21 | メルク・シャープ・アンド・ドーム・コーポレーション | ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体 |
| AU2009222122A1 (en) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| EP2413932A4 (de) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | Hemmer der akt-aktivität |
| EP2429293B1 (de) | 2009-05-12 | 2014-10-29 | Bristol-Myers Squibb Company | KRISTALLINE FORMEN VON (S)-7-([1,2,4]TRIAZOL[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLORPHENYL)-1,2,3,4-TETRAHYDROISOCHINOLIN UND IHRE VERWENDUNG |
| ES2662072T3 (es) | 2009-05-12 | 2018-04-05 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma |
| KR20120034644A (ko) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도 |
| KR101485645B1 (ko) | 2009-10-14 | 2015-01-22 | 머크 샤프 앤드 돔 코포레이션 | ｐ53 활성을 증가시키는 치환된 피페리딘 및 그의 용도 |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| CN107090456B (zh) | 2010-08-02 | 2022-01-18 | 瑟纳治疗公司 | 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制 |
| HUE044815T2 (hu) | 2010-08-17 | 2019-11-28 | Sirna Therapeutics Inc | Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| CN103732592A (zh) | 2011-04-21 | 2014-04-16 | 默沙东公司 | 胰岛素样生长因子-1受体抑制剂 |
| US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| EP3919620A1 (de) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Zusammensetzungen mit kurzer interferierender nukleinsäure (sina) |
| CA2882950A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| LT2925888T (lt) | 2012-11-28 | 2018-01-10 | Merck Sharp & Dohme Corp. | Vėžio gydymo kompozicijos ir būdai |
| BR112015013611A2 (pt) | 2012-12-20 | 2017-11-14 | Merck Sharp & Dohme | composto, e, composição farmacêutica |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2016025322A1 (en) * | 2014-08-09 | 2016-02-18 | Purdue Research Foundation | Design and development of neurokinin-1 receptor-binding agent delivery conjugates |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| US20210277009A1 (en) | 2018-08-07 | 2021-09-09 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US20210309688A1 (en) | 2018-08-07 | 2021-10-07 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2922591A1 (de) * | 1979-06-02 | 1980-12-04 | Basf Ag | Verfahren zur herstellung von pyrazolen |
| GB8824400D0 (en) * | 1988-10-18 | 1988-11-23 | Glaxo Group Ltd | Chemical compounds |
| DE3918979A1 (de) * | 1989-06-10 | 1990-12-13 | Basf Ag | Verfahren zur herstellung von pyrazol und dessen derivaten |
| WO1991009844A1 (en) * | 1990-01-04 | 1991-07-11 | Pfizer Inc. | Substance p antagonists |
| DE4028393A1 (de) * | 1990-09-07 | 1992-03-12 | Basf Ag | Verfahren zur herstellung von 3-methylpyrazol |
| EP0499313B1 (de) * | 1991-02-11 | 1997-06-11 | MERCK SHARP & DOHME LTD. | Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung |
| WO1993004040A1 (en) * | 1991-08-20 | 1993-03-04 | Merck Sharp & Dohme Limited | Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
-
1993
- 1993-07-20 JP JP6503945A patent/JPH07508993A/ja active Pending
- 1993-07-20 WO PCT/GB1993/001525 patent/WO1994002461A1/en active IP Right Grant
- 1993-07-20 ES ES93917877T patent/ES2124318T3/es not_active Expired - Lifetime
- 1993-07-20 AT AT93917877T patent/ATE173725T1/de not_active IP Right Cessation
- 1993-07-20 US US08/379,622 patent/US5561130A/en not_active Expired - Fee Related
- 1993-07-20 AU AU47139/93A patent/AU675447B2/en not_active Ceased
- 1993-07-20 CA CA002138650A patent/CA2138650A1/en not_active Abandoned
- 1993-07-20 EP EP93917877A patent/EP0652866B1/de not_active Expired - Lifetime
- 1993-07-20 DE DE69322275T patent/DE69322275T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU675447B2 (en) | 1997-02-06 |
| US5561130A (en) | 1996-10-01 |
| ES2124318T3 (es) | 1999-02-01 |
| EP0652866A1 (de) | 1995-05-17 |
| WO1994002461A1 (en) | 1994-02-03 |
| JPH07508993A (ja) | 1995-10-05 |
| AU4713993A (en) | 1994-02-14 |
| CA2138650A1 (en) | 1994-02-03 |
| ATE173725T1 (de) | 1998-12-15 |
| DE69322275D1 (de) | 1999-01-07 |
| EP0652866B1 (de) | 1998-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69322275D1 (de) | Azazyklische verbindungen | |
| ES2163410T3 (es) | Derivados de benzodiazepina. | |
| DE69516853D1 (de) | Aralkoxy und aralkylthio substituierte azacyclische verbindungen als tachykinin antagonisten | |
| DE69208089T2 (de) | Aromatische verbindungen diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische verwendung | |
| ES2141174T3 (es) | 4-arilmetiloximetil piperidinas como antagonistas de taquiquinina. | |
| DK357980A (da) | Fremgangsmaade til fremstilling af propenylaminer | |
| ES2093523T3 (es) | Catalizadores quirales y reacciones de epoxidacion catalizadas por los mismos. | |
| DE69303583T2 (de) | 15-Deoxyspergualin analoge Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Therapeutika zur Unterdrückung der Immunabwehr | |
| DK0553016T3 (da) | Hidtil ukendte naphtalenamider og -sulfonamider, fremgangsmåder til deres fremstilling samt farmaceutiske midler indeholdende dem | |
| DE69414106D1 (de) | Herbizide verbindungen | |
| NO983691L (no) | Forbindelser tilh°rende amidiniumfamilien, farmas°ytiske preparater inneholdende disse samt anvendelse derav | |
| DK0749438T3 (da) | Hidtil ukendte silylforbindelser og deres anvendelse | |
| PT689534E (pt) | Derivados amida como ligandos de 5-ht1a | |
| DE69026816T2 (de) | Bizyklische amino-substituierte verbindungen | |
| ATE71948T1 (de) | Guanidin-verbindungen, die ein substituiertes tetraphenylboration enthalten, verfahren zu deren herstellung und verwendung dieser verbindungen waehrend der peptid-synthese. | |
| ES8900162A1 (es) | Procedimiento para la obtencion de 3-acilaminobenzisotiazol-s,s-dioxidos | |
| DE69616357T2 (de) | Benzocycloalken-verbindungen mit bindungsaffinität an den melatonin-rezeptor, ihre herstellung und verwendung | |
| DK32287D0 (da) | 3-acylaminomethyl-imidazo(1,2-a)pyridinderivater, fremgangsmaade til fremstilling deraf samt laegemiddel indeholdende saadanne derivater | |
| ATE109475T1 (de) | Benzothiazolinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel. | |
| DK73289D0 (da) | Basisk substituerede 5-halogen-thienoisothiazol-3(2h)-on-1,1-dioxider, fremgangsmaade til fremstilling af saadanne forbindelser og farmaceutiske praeparater indeholdende disse | |
| SE8404906L (sv) | Fluoralkylerade karbapenemderivat | |
| GB9226857D0 (en) | Pharmaceutical compositions | |
| ES2149216T3 (es) | Utilizacion de derivados de piperazina para el tratamiento de trastornos cognoscitivos. | |
| NO962251L (no) | Substituerte aminoalkyaminopyridiner | |
| DK0599732T3 (da) | 1-phenylbicyklo 2.2.2 octanderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |